

**Supplementary Material** - Clinical and pharmacoeconomic evaluation of fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory *Clostridioides difficile* infection

## Recurrent *Clostridioides difficile* infection

**Table S1** Clinical outcome of patients with recurrent *Clostridioides difficile* infection

	<b>Fidaxomicin group (n=110)</b>	<b>Vancomycin group (n=112)</b>	<b>p value</b>
<b>Days with CDI-associated diarrhea, median (IQR)</b>	4 (2-6)	4 (2-6)	0.203 <sup>a</sup>
<b>Symptom reduction on day 10 of CDI therapy, n (%)</b>	108 (98)	95 (85)	<b>&lt;0.001<sup>b</sup></b>
<b>New CDI recurrence within 90 days, n (%)</b>	25 (23)	47 (42)	<b>0.002<sup>b</sup></b>
<b>90-day mortality, n (%)</b>	13 (12)	13 (12)	0.899 <sup>b</sup>
<b>Days of initial hospitalisation, median (IQR)</b>	20 (10-46)	26 (11-54)	0.361 <sup>a</sup>

Abbreviations: IQR, interquartile range; CDI, *Clostridioides difficile* infection

<sup>a</sup> Mann-Whitney U Test; <sup>b</sup> Pearson's chi square test

**Table S2** Direct treatment costs for patients with recurrent *Clostridioides difficile* infection in Euro

	<b>Fidaxomicin group (n=110)</b>	<b>Vancomycin group (n=112)</b>	<b>p value</b>
<b>Hospitalisation costs<sup>l, b</sup>, n (%)</b>	79 (72)	80 (71)	0.949 <sup>d</sup>
Costs per patient, mean (95% CI)	19,364 (13,490-25,239)	18,619 (13,191-24,049)	0.872 <sup>a</sup>
<b>Hospitalisation costs (Year 2024)</b>			
Costs per patient, mean (95% CI)	19,539 (14,257-24,821)	20,231 (14,729-25,733)	0.844 <sup>a</sup>
<b>Overall recurrent/ refractory CDI drug acquisition costs<sup>c</sup>, n (%)</b>	110 (100)	110 (98)	0.498 <sup>e</sup>
Costs per patient, mean (95% CI)	2,404 (2,228-2,591)	1,307 (1,085-1,543)	<b>&lt;0.001<sup>a</sup></b>
<b>Overall direct treatment costs<sup>b, c</sup>, n (%)</b>	110 (100)	112 (100)	-
Costs per patient, mean (95% CI)	16,311 (11,749-20,873)	14,583 (10,443-18,723)	0.593 <sup>a</sup>
<b>Overall direct treatment costs (Year 2024)</b>			
Costs per patient, mean (95% CI)	16,437 (12,254-20,619)	15,734 (11,493-19,976)	0.826 <sup>a</sup>

Abbreviations: CI, Confidence interval; CDI, *Clostridioides difficile* infection

<sup>l</sup> n-values differ due to missing data; <sup>a</sup> Bootstrapped t-test (independent samples, two sided); <sup>b</sup> Based on G-DRGs from 2013 to 2023; <sup>c</sup> Based on Rote Liste® prices from 2024; <sup>d</sup> Pearson chi-square test (two-tailed); <sup>e</sup> Fisher's exact test

## Refractory *Clostridioides difficile* infection

**Table S3** Clinical outcome of patients with refractory *Clostridioides difficile* infection

	Fidaxomicin group (n=62)	Vancomycin group (n=61)	p value
<b>Days with CDI-associated diarrhea, median (IQR)</b>	8 (5-10)	6 (4-12)	0.488 <sup>a</sup>
<b>Symptom reduction on day 10 of CDI therapy, n (%)</b>	55 (89)	52 (85)	0.648 <sup>b</sup>
<b>New CDI recurrence within 90 days, n (%)</b>	11 (18)	17 (28)	0.181 <sup>b</sup>
<b>90-day mortality, n (%)</b>	12 (19)	9 (15)	0.497 <sup>b</sup>
<b>Days of initial hospitalisation, median (IQR)</b>	40 (28-65)	37 (25-49)	0.191 <sup>a</sup>

Abbreviations: IQR, interquartile range; CDI, *Clostridioides difficile* infection

<sup>a</sup> Mann-Whitney U Test; <sup>b</sup> Pearson's chi square test

**Table S4** Direct treatment costs for patients with refractory *Clostridioides difficile* infection in Euro

	Fidaxomicin group (n=62)	Vancomycin group (n=61)	p value
<b>Hospitalisation costs<sup>l, b</sup>, n (%)</b>	53 (85)	55 (90)	0.428 <sup>d</sup>
Costs per patient, mean (95% CI)	19,694 (13,650-25,738)	19,487 (14,617-24,356)	0.960 <sup>a</sup>
<b>Hospitalisation costs (Year 2024)</b>			
Costs per patient, mean (95% CI)	20,662 (15,334-25,990)	20,330 (16,219-24,440)	0.924 <sup>a</sup>
<b>Overall recurrent/ refractory CDI drug acquisition costs<sup>c</sup>, n (%)</b>	62 (100)	60 (98)	0.496 <sup>e</sup>
Costs per patient, mean (95% CI)	2,412 (2,126-2,794)	1,164 (876-1,519)	<b>&lt;0.001<sup>a</sup></b>
<b>Overall direct treatment costs<sup>b, c</sup>, n (%)</b>	62 (100)	61 (100)	-
Costs per patient, mean (95% CI)	19,247 (13,822-24,672)	18,715 (14,102-23,328)	0.870 <sup>a</sup>
<b>Overall direct treatment costs (Year 2024)</b>			
Costs per patient, mean (95% CI)	20,074 (15,197-24,951)	19,475 (15,438-23,512)	0.841 <sup>a</sup>

Abbreviations: CI, Confidence interval; CDI, *Clostridioides difficile* infection

<sup>l</sup> n-values differ due to missing data; <sup>a</sup> Bootstrapped t-test (independent samples, two sided); <sup>b</sup> Based on G-DRGs from 2013 to 2023; <sup>c</sup> Based on Rote Liste® prices from 2024; <sup>d</sup> Pearson chi-square test (two-tailed); <sup>e</sup> Fisher's exact test